Valneva , a specialty vaccine company, today provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate,... View Article
Author Archives for Adeline Chauvigné
Valneva provides regulatory update on its COVID-19 vaccine candidate
10 May 2025Valneva , a specialty vaccine company, today provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate,... View Article
HTL announces its incubator’s equity investment in GelMEDIX, an early-stage biotech aiming at revolutionizing ocular and regenerative therapies
This partnership represents the first equity investment of an incubator created by HTL, pioneer and world leader in the development... View Article
HTL announces its incubator’s equity investment in GelMEDIX, an early-stage biotech aiming at revolutionizing ocular and regenerative therapies
10 May 2025This partnership represents the first equity investment of an incubator created by HTL, pioneer and world leader in the development... View Article
Pherecydes Pharma extends its intellectual property in China
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the granting... View Article
Pherecydes Pharma extends its intellectual property in China
10 May 2025Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the granting... View Article
New member | ODPM
Founded in 2010, ODPM creates, develops and markets innovative and high performance solutions for personalized medicine in oncology. Its services are emanations of the... View Article
New member | ODPM
10 May 2025Founded in 2010, ODPM creates, develops and markets innovative and high performance solutions for personalized medicine in oncology. Its services are emanations of the... View Article
Pherecydes Pharma receives a favorable opinion from the Ethics Committee to initiate the PhagoDAIR study
PhagoDAIR is a phase I/II clinical study for the treatment of osteoarticular infections of prostheses due to Staphylococcus aureus This Ethics... View Article
Pherecydes Pharma receives a favorable opinion from the Ethics Committee to initiate the PhagoDAIR study
10 May 2025PhagoDAIR is a phase I/II clinical study for the treatment of osteoarticular infections of prostheses due to Staphylococcus aureus This Ethics... View Article
Valneva and Pfizer report further positive phase 2 data for Lyme disease vaccine candidate
Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 Sub-analysis compared the immunogenicity of VLA15... View Article
Valneva and Pfizer report further positive phase 2 data for Lyme disease vaccine candidate
10 May 2025Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 Sub-analysis compared the immunogenicity of VLA15... View Article
Transnational EU-project CE4BIG on Cluster Management Excellence and SME support draws to a close
In the framework of CE4BIG (Cluster Excellence for Business, Innovation and Growth in the health sector), supported bythe EU COSME... View Article
Transnational EU-project CE4BIG on Cluster Management Excellence and SME support draws to a close
10 May 2025In the framework of CE4BIG (Cluster Excellence for Business, Innovation and Growth in the health sector), supported bythe EU COSME... View Article
Valneva announces initiation of adolescent phase 3 trial for its single-shot chikungunya vaccine candidate
CEPI-funded trial intended to support potential label expansion in this age group Valneva, a specialty vaccine company, today announced the... View Article
Valneva announces initiation of adolescent phase 3 trial for its single-shot chikungunya vaccine candidate
10 May 2025CEPI-funded trial intended to support potential label expansion in this age group Valneva, a specialty vaccine company, today announced the... View Article
Ose Immunotherapeutics: license agreement with Veloxis Pharmaceuticals
OSE Immunotherapeutics Announced Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in... View Article
Ose Immunotherapeutics: license agreement with Veloxis Pharmaceuticals
10 May 2025OSE Immunotherapeutics Announced Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in... View Article
CUREETY, the French start-up specialized in data and remote-monitoring in oncology, raises €5 million
The financing round was led by French mutual insurance companies, with the support of Cureety’s existing investors, bank pool and... View Article
CUREETY, the French start-up specialized in data and remote-monitoring in oncology, raises €5 million
10 May 2025The financing round was led by French mutual insurance companies, with the support of Cureety’s existing investors, bank pool and... View Article